Kymab raises €94m for mAb pipeline
UK-based biopharma group Kymab has brought a new backer from China on board. With the help from ORI Healthcare Fund, Kymab secured a US$100m Series C financing.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 241 entries already.
Entries by Uta Mommert
Performance in Clinical Trials: Pharmatio GmbH with new Portfolio
Pharmatio GmbH, already established in the monitoring and site liaison of clinical trials, has restructured its services. With Clinical Trial Liaison, the sponsors of clinical trials can ensure the patient recruitment and effectiveness of their clinical trials. The Clinical Trial Task Force masters difficult or unforeseen challenges in clinical trials, and High Quality Monitoring ensures that Pharmatio ensures all-time inspection readiness of clinical trial sites.
Belgian Fund+ raises €125m for biotechs
Investors are once again flocking to back biotechs in Europe. Belgian Life Sciences fund Fund+ has raised €125m – a quarter more than initially anticipated.
ETH builds cyborg bacteria
Part microbe, part machine: cyborg bacteria developed at ETH Zurich could revolutionise the biotechnological production of molecules. The bacteria have been engineered to respond to light signals.
Nordic Nanovector in blood cancer pact
Nordic Nanovector is expanding its foothold in cancer-fighting ADCs. The Oslo-based biotech has inked a leukaemia pact with Wilex subsidiary Heidelberg Pharma.
EMA unveils trial data
Trial transparency has been a hotly debated topic over the last months, but now, the EMA is turning words into action. The agency will allow public access to clinical trial reports, starting now.
Dilaforette: Going public with a new name
New name, new outlook: blood disorder specialist Dilaforette will be known as Modus Therapeutics Holding from here on out. The Swedish company also announced an intention to float in the near future.
Ysios closes €126m BioFund
Spanish start-ups, take heed: One of the biggest biotech funds in Southern Europe has just been closed by Ysios Capital. The Spanish venture firm raised €126.4m to be reinvested in European biotech, medtech and diagnostics companies.
Diabetes giant cuts jobs
Danish insulin maker Novo Nordisk tries to relieve financial pressure by laying off 1,000 staff. The step was necessary due to challenges on the US market, the company said.
BioNTech teams up with Genentech
German immuno-oncology play BioNTech has entered into a collaboration with Roche’s Genentech to develop novel mRNA-based, individualised cancer vaccines. The deal will net BioNTech €278m.